Bristol Myers Shares Fall About 3% After Mixed Lung Drug Trial Results
Shares fell roughly 3% in midday trading Monday after Bristol Myers Squibb reported mixed late-stage trial results in scarring lung disease: the lower dose succeeded, while the higher dose missed statistical significance.
Bristol Myers Squibb (BMY) shares fell roughly 3% in midday trading on Monday, reversing opening gains, after the company reported mixed results from a late-stage trial in scarring lung disease — the study succeeded only at the lower dose tested while the higher dose fell short of statistical signi…